Home > Journals > Medicine > Hématologie > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Hématologie
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

IL-12: basic concepts and role in hematopoiesis


Hématologie. Volume 2, Number 5, 387-95, Septembre - Octobre 1996, REVUES ET MINI-REVUES

Résumé   Article gratuit  

Author(s) : Laurence Zitvogel, Cécile Pardoux, Salem Chouaib

Summary : IL-12 is heterodimeric cytokine witch has a long half-life and is mainly secreted by denditric cells, macrophages, EBV-transformed lymphoblastoid B cells and neutrophils. IL-12 subserves a variety of biological functions on activated NK and T cells such as proliferation, production of IFNgamma and differentiation of CD4+ T cells towards a Th1 pattern, and links innate and cognate immune responses. Following systemic or paracrine administration, IL-12 has potent antitumor effects and can cure infectious opportunistic diseases in mice. The role of IL-12 in hematopoiesis has been investigated, both in vitro and in vivo, in mouse and man. IL-12, like IL-6 and IL-11, in a synergistic (along with IL-3, FL, SCF) and direct fashion can enhance the growth of hematopoietic progenitor cells in vitro, whereas it can indirectly suppress (through IFNgamma and TNFalpha) hematopoiesis in vitro. IL-12 can potently and synergistically enhance colony formation of primitive bone marrow progenitor cells in combination with other cytokines. The endogenous role of IL-12 in hematopoiesis remains ill-defined. The role of IL-12 in development of hematopoiesis has been suggested in mouse models. However, following systemic administration of high doses of IL-12 in rodents and primates, anemia, neutropenia, lymphopenia (adverse effects of enhanced IFNgamma production), and splenomegaly (with both progenitor mobilization from bone marrow to extramedullary sites and enhanced proliferation of peripheral progenitors) occurred. In the phase I clinical trial for cancer and AIDS utilizing recombinant daily intravenous injections of IL-12, patients developed leucopenia. Finally, IL-12 could inhibit graftversus host disease in murine models.

Keywords : interleukin-12, growth factors, hematopoiesis, progenitors, cellular mediated immune response.

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]